BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 19519285)

  • 1. Emerging drugs for acute graft-versus-host disease.
    Khaled Y; Reddy P; Krijanovski O
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-host disease.
    Choi S; Reddy P
    Panminerva Med; 2010 Jun; 52(2):111-24. PubMed ID: 20517195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
    Johnston L
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic graft-versus-host disease: is there an alternative to the conventional treatment?
    Gaziev D; Galimberti M; Lucarelli G; Polchi P
    Bone Marrow Transplant; 2000 Apr; 25(7):689-96. PubMed ID: 10745252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Remberger M
    Haematologica; 2005 Jul; 90(7):870. PubMed ID: 15996922
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of infections complicating allogeneic hematopoietic stem cell transplantation.
    Hiemenz JW
    Semin Hematol; 2009 Jul; 46(3):289-312. PubMed ID: 19549581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease: emerging concepts in prevention and therapy.
    Dean RM; Bishop MR
    Curr Hematol Rep; 2003 Jul; 2(4):287-94. PubMed ID: 12901325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
    Pollack SM; O'Connor TP; Hashash J; Tabbara IA
    Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis and treatment of acute graft-versus-host disease.
    Chao NJ; Chen BJ
    Semin Hematol; 2006 Jan; 43(1):32-41. PubMed ID: 16412787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
    Laport GG
    Curr Hematol Rep; 2003 Jan; 2(1):49-56. PubMed ID: 12901154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Many faces of graft-versus-host disease.
    Peñas PF; Zaman S
    Australas J Dermatol; 2010 Feb; 51(1):1-10; quiz 11. PubMed ID: 20148830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.